The active compound in magic mushrooms – psilocybin – seems to be at least as effective as a commercially-available antidepressant in a phase 2 trial, and may work more quickly.
Compass Pathways and its potential magic mushroom depression drug went public last week – and now psychedelic therapy firm Mind Medicine is aiming to follow suit by up-listing its shares on
UK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its depression treatment based on psilocybin – an active ingredient that can be found in magic m